Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–3 of 3 stories
Eli Lilly has decided to discontinue three therapies, including a gene therapy for dementia acquired through its $1.04 billion purchase of Prevail Therapeutics. This move aligns with Lilly's strategy to focus on its GLP-1 pipeline.
A new NIH-funded study establishes a clear link between severe chronic traumatic encephalopathy (CTE) and increased dementia risk. This research could influence future therapeutic strategies and patient management for individuals with a history of head trauma.
The Advisory Council on Alzheimer's Research, Care, and Services will hold its first meeting of 2026 to introduce new members and discuss strategies to alleviate the burden of Alzheimer's disease. This meeting aims to enhance collaboration among federal agencies in addressing Alzheimer's and related dementias.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.